Compare · BWV vs NVO
BWV vs NVO
Side-by-side comparison of Blue Water Biotech Inc. (BWV) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BWV and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $196.28B.
- NVO has hit the wire 8 times in the past 4 weeks while BWV has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for BWV).
- Company
- Blue Water Biotech Inc.
- Novo Nordisk A/S
- Price
- $0.18-4.63%
- $43.97+2.76%
- Market cap
- -
- $196.28B
- 1M return
- -
- -6.43%
- 1Y return
- -
- -45.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Blue Water Biotech Inc.
Blue Water Vaccines, Inc., a biotechnology company, engages in the research and development of vaccines to prevent infectious diseases worldwide. The company's lead vaccine programs that are under preclinical development include BWV-101, an influenza vaccine; and BWV-102, a H1 pre-pandemic vaccine. It also has other pipeline under preclinical development comprising BWV-201, a streptococcus pneumoniae induced acute otitis media vaccine program; BWV-301, a norovirus-rotavirus vaccine program; and BWV-302, a norovirus-malaria vaccine program. The company was incorporated in 2018 and is based in Cincinnati, Ohio.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BWV
- SEC Form 3 filed by new insider Singh Ajit
- SEC Form 3 filed by new insider Meier Thomas
- SEC Form S-1 filed by Blue Water Biotech Inc.
- SEC Form PRE 14A filed by Blue Water Biotech Inc.
- Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form S-8 filed by Blue Water Biotech Inc.
- Blue Water Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)
- Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care